---
title: "Obefazimod (ABX464) in Ulcerative colitis: Diagnosis"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Diagnosis. Topics: Diagnostic approach: clinical, biological, endoscopic, and histological findings; ACG 2025 key concept statements: suspicion, exclusion of infection, and colonoscopy with biopsy; ACG 2025 recommendations: Clostridioides difficile testing and serologic antibody testing; Endoscopy and histology: extent by the Montreal classification; 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/diagnosis"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Diagnostic approach: clinical, biological, endoscopic, and histological findings

> “Patients usually present with bloody diarrhoea, and the diagnosis is based on a combination of clinical, biological, endoscopic, and histological findings.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “UC is diagnosed based on the presence of symptoms with confirmation of disease via colonoscopy and biopsy.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.5-2"></a>

### ACG 2025 key concept statements: suspicion, exclusion of infection, and colonoscopy with biopsy

> “The diagnosis of UC should be suspected in patients with hematochezia, increased stool frequency, or bowel urgency.”
> “Infectious etiologies should be excluded at the time of diagnosis.”
> “Colonoscopy with intubation of the ileum and biopsies of affected and unaffected areas should be obtained to confirm the diagnosis of UC, with mucosal biopsies interpreted by a pathologist, preferably one with expertise in gastrointestinal pathology.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-3"></a>

### ACG 2025 recommendations: Clostridioides difficile testing and serologic antibody testing

> “We recommend stool testing to rule out Clostridioides difficile in patients suspected of having UC (Strong recommendation, very low quality of evidence).”
> “We recommend against serologic antibody testing to establish or rule out a diagnosis of UC (Strong recommendation, very low quality of evidence).”
> “We recommend against serologic antibody testing to determine the prognosis of UC (Strong recommendation, very low quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-4"></a>

### Endoscopy and histology: extent by the Montreal classification

> “The diagnosis of UC requires a lower gastrointestinal endoscopic examination with histologic confirmation. For most patients, a complete colonoscopy and direct visualization of the terminal ileum should be performed.”
> “Endoscopically, UC most often presents as a continuously inflamed segment involving the distal rectum and extending proximally. Endoscopic features of inflammation include loss of vascular markings, granularity and friability of the mucosa, erosions, and in the setting of severe inflammation, deep ulcerations and spontaneous bleeding.”
> “The extent of the disease should be characterized according to the currently used Montreal classification as proctitis (E1, usually defined as ≤15 cm of inflammation), left-sided colitis (E2, defined as more than proctitis, but the extent stops at or distal to the splenic flexure), or extensive colitis (E3, defined as extension proximal to the splenic flexure, with pancolitis defining the entire rectum and colon including the cecum) (Figure 1) (33,34).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-5"></a>

### Biomarkers: fecal calprotectin, C-reactive protein, and serology

> “The pooled sensitivity and specificity of elevated FC for diagnosis of UC are 0.88 and 0.79, respectively, with a modest positive likelihood ratio of 4.2 and a more clinically meaningful negative likelihood ratio of 0.15.”
> “However, up to a quarter of patients with endoscopically active disease may have a normal CRP and the frequency of elevation is lower in individuals with mild endoscopic activity [reference], so benchmarking the CRP at the time of diagnosis is key to its use and interpretation in later management.”
> “Serologic markers such as perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) may be found in up to 70% of patients with UC, and combination of negative anti-Saccharomyces cerevisiae (ASCA) antibodies with elevated pANCA levels have been proposed to facilitate establishing a diagnosis of UC (59,60). However, the pooled sensitivity of antibody testing for diagnosis of UC is low, and such markers are not used for establishing or ruling out a diagnosis of UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “People with UC require monitoring of symptoms and biomarkers of inflammation (eg, fecal calprotectin), and require colonoscopy at 8 years from diagnosis for surveillance of dysplasia. Risk stratification by disease location (eg, Montreal Classification) and disease activity (eg, Mayo Score) can guide management of UC.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.5-6"></a>

### Disease activity assessment: Mayo score and the trial definition of moderately to severely active disease

> “Several quantitative disease activity indices are available (64) including the Mayo score (Table 5) (65), Seo Index (66), Rachmilewitz Index (67), Simple Clinical Colitis Activity Index (SCCAI) (Table 6) (68), PRO2 (69), and the pediatric UC activity index (70).”
> “Inclusion criteria for clinical trials of agents for moderately to severely active UC have required components such as (i) inability to taper off prednisone, (ii) prior failure of immunosuppressants, and (iii) moderate-to-severe disease defined by Modified Mayo score (including the specific endoscopy subscore). In clinical trials, the definition of clinical remission has been a MES of 0 or 1, stool frequency of ≤1, and absence of rectal bleeding.”
> “The MES is frequently used in clinical trials and is simple to use in clinical practice, ranging from 0 for normal or inactive disease to 3 for severely active disease (65).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-7"></a>

### Intestinal ultrasound for monitoring disease activity

> “New for these updated guidelines is a defined role for intestinal ultrasound (IUS) as a tool to measure UC disease activity and monitor response to therapy or disease relapse.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-8"></a>

### Diagnostic delay: mean 2.0 years from symptom onset

> “The mean duration between UC symptom onset and UC diagnosis was 2.0 years (SD, 5.4); 42% of patients waited ≥1 year for diagnosis, and 11% of patients had waited ≥5 years.”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
